The US Food and Drug Administration (FDA) has approved Cymbalta for chronic musculoskeletal pain - in other words, chronic back pain and osteoarthritis pain. According to Eli Lilly, the makers and marketers of Cymbalta (duloxetine HCI), this is the 5th indication for Cymbalta approved by the FDA. The medication is taken once a day. Duloxetine, with brand names Cymbalta, Ariclaim, Xeristar and Yentreve is a serotonin-norepinephrine reuptake inhibitor. It is an effective drug for major depressive disorder and has been demonstrated in trials to be as effective as venlafaxine for GAD (generalized anxiety disorder). Submission for approval for stress urinary incontinence was turned down by the FDA because of liver concerns and suicidal events - it is, however, approved for this condition in Europe.
Chronic lower back pain may be linked to a recently defined form of inflammatory arthritis known as axial spondyloarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. Spondyloarthritis is the overall name for a family of inflammatory rheumatic diseases including ankylosing spondylitis that can affect the spine and joints, ligaments and tendons. These diseases can cause fatigue and pain or stiffness in the back, neck, hands, knees, and ankles as well as inflammation of the eyes, skin, lungs, and heart valves. While there is no course of prevention at this time, early treatment by a rheumatologist can reduce discomfort and loss of functionality. Chronic lower back pain is one of the most common pain syndromes with an unknown cause.
Low back pain is extremely common, affecting four in five Australians at some point in their lives. The pain can be debilitating and people often want to know what's causing it, but in about 85% of cases the cause is non-specific. Doctors, pharmacists, physiotherapists and osteopaths may be sought by people to help manage their low back pain. Recognising this, NPS's latest education program for health professionals looks at treatment options in acute low back pain and emphasises that in the absence of indicators of more serious problems, diagnostic imaging is usually not necessary. "Most cases of acute low back pain are not due to any serious injury, disease or damage to the spine and aren't associated with lasting damage, " NPS clinical adviser, Danielle Stowasser said. "People have come to expect a scan or x-ray to diagnose the problem, but they need to understand diagnostic imaging isn't usually necessary in acute non-specific low back pain.
Replication Medical Receives Grant Of Nearly 250,000.00 On The Heels Of Successful Clinical Results With Its Innovative GelStix TM Treatment
Replication Medical, Inc., a developer of proprietary, hydrogel based products for spine and other surgical applications, reported that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244, 479 based on Replication Medical's 2009 GelStix related research expenditures. The GelStix product is intended to treat chronic lower back pain which impacts nearly 10-15% of adults and is associated with a condition known as degenerative disc disease. Early stage treatments for degenerative disc disease (DDD) include non-surgical pain management such as anti-inflammatory medications and exercise programs. Traditional surgical interventions include spinal fusion and disc replacement, which can be debilitating and risky for patients, especially the elderly.
Results of a Toronto Western Hospital study show that patients suffering back pain get quicker diagnosis and treatment when a Nurse Practitioner conducts the first examination. Traditionally, patients face long and anxiety-ridden wait times - up to 52 weeks - before an initial examination by a spine surgeon. Results from the year long TWH study showed wait times for patients examined by a Nurse Practitioner were significantly shorter, ranging from 10 to 21 weeks. "Waiting times for specialty consultations in public healthcare systems worldwide are lengthy and impose undue stress on patients waiting for further information and management of their condition" says study author and Nurse Practitioner Ms. Angela Sarro. "Back pain can be very unpleasant and debilitating and 85 per cent of us will experience it at some point in our lives.